Document is current
Any future updates will be listed below
-
Authors
Lee, Jaewon J.
Aldakkak, Mohammed
Morrison, Ashley B.
Thalji, Sam Z.
Peng, Xianlu L.
Li, Yan
Gulley, Margaret L.
Borazanci, Erkut H.
Tsai, Susan
Rashid, Naim U.
Yeh, Jen Jen
-
Funding
Funding for this research was provided by:
National Institutes of Health (U01CA274298)
National Institutes of Health (R01CA199064)
National Institutes of Health (R01CA199064)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 27 November 2025
First Online: 20 December 2025
Competing interests
: PurIST was licensed to GeneCentric Therapeutics and subsequently licensed to Tempus AI. Neither GeneCentric nor Tempus was involved in the design of this study. J.J.Y. and N.U.R. are patent holders of PurIST (WO2020205993A1). E.H.B. has consulting or advisory roles at NanOlogy, BPGbio, ClearNote Health, Merus, VCN Biosciences, Corcept Therapeutics, and Arcus Biosciences, and HonorHealth Research Institute receives research funding from Bristol-Myers Squibb, Pharmacyclics, Idera, Daiichi Sankyo, Minneamrita Therapeutics, Lilly, Merck, Helix, BioNTech AG, Corcept Therapeutics, and Biosplice. Remaining authors declare no financial or non-financial competing interests.
